Abstract
The blood-brain barrier (BBB) presents a major challenge in the development of therapeutics for central nervous system (CNS) disorders. This selective permeability barrier restricts the passage of many potential drugs, limiting treatment efficacy. Overcoming the BBB is crucial for the successful delivery of neurotherapeutics, including small molecules, biologics, and gene therapies. This article explores the various strategies currently employed to bypass or modulate the BBB, such as drug delivery systems, nanotechnology, and biological agents. These methods have shown promise in improving drug bioavailability in the brain and advancing the treatment of neurodegenerative diseases, brain cancers, and other CNS conditions.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.